Feb. 10, 2023

A Billion-Dollar Aldosterone Synthase Inhibitor, an Oral KRASG12D Inhibitor Entering Development, and 14 More Molecules in the News

drughunter.com
Drug Hunter Team

In this update of small molecules in the news we will cover recent:

  • (B/M)illion-Dollar Molecules: recent M&A’s, IPOs, and other fundraising

  • Molecules in Motion: clinical trial updates and FDA filings

  • Where Are They Now? updates on past Drug Hunter Molecules of the Month

  • Potential Upcoming Approvals: recent NDA filings and upcoming PDUFA dates

Want updates like this straight to your inbox? Sign up for our weekly newsletter here.

Million-Dollar Molecules

baxdrostat 

This highly selective, oral aldosterone synthase (CYP11B2) inhibitor is being acquired by AstraZeneca via CinCor in a $1.8B transaction. The molecule is in several Ph. II trials (0.5-2 mg QD) for hypertension, CKD, and primary aldosteronism, appears to have demonstrated dose-dependent PK/PD and blood pressure response, and appears to be well-tolerated so far. CinCor licensed the molecule from Roche (RO6836191).

Loading...

twitterlinkedinemail

Other articles you may be interested in